This past year saw major shifts affecting patent adjudication, prosecution strategy, biotechnology claiming, artificial ...
Amid a year of significant disruption, the US Securities and Exchange Commission (SEC) initiated far fewer enforcement actions involving ...
Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results